75715-89-8
Chemical Structure
Leukotriene E4
Synonym(s): LTE4
- CAS No.: 75715-89-8
- Formula:C23H37NO5S
- Molecular Weight:439.61
IUPAC Name: (5S,6R,7E,9E,11Z,14Z)-6-(((R)-2-amino-2-carboxyethyl)thio)-5-hydroxyicosa-7,9,11,14-tetraenoic acid
InChIKey: OTZRAYGBFWZKMX-FRFVZSDQSA-N
SMILES: CCCCC/C=C\C/C=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O
Biological Activity:
Leukotriene E4 (LTE4) is a stable final metabolite of cysteinyl leukotrienes, produced by immune cells such as mast cells and eosinophils. Leukotriene E4 serves as a key biomarker for evaluating asthma severity, Aspirin (HY-14654) sensitivity, and mast cell activation disorders. Leukotriene E4 is a full functional agonist of CysLT1R, which induces sustained intracellular calcium mobilization and Erk phosphorylation. Leukotriene E4 mediates inflammation in a P2Y12 receptor-dependent manner. Leukotriene E4 can be used in the research of asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory diseases[1][2][3].
The product specifications provided below refer solely to the active content of Leukotriene E4.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Leukotriene E4 | 99.61% | Leukotriene E4 (LTE4) is a stable final metabolite of cysteinyl leukotrienes, produced by immune cells such as mast cells and eosinophils. Leukotriene E4 serves as a key biomarker for evaluating asthma severity, Aspirin (HY-14654) sensitivity, and mast cell activation disorders. Leukotriene E4 is a full functional agonist of CysLT1R, which induces sustained intracellular calcium mobilization and Erk phosphorylation. Leukotriene E4 mediates inflammation in a P2Y12 receptor-dependent manner. Leukotriene E4 can be used in the research of asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory diseases. The product specifications provided below refer solely to the active content of Leukotriene E4. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Leukotriene E4-d5 | 98.5% | Leukotriene E4-d5 (LTE4-d5) is the d5-labeled Leukotriene E4 (HY-113465). Leukotriene E4 is a stable final metabolite of cysteinyl leukotrienes, produced by immune cells such as mast cells and eosinophils. Leukotriene E4 serves as a key biomarker for evaluating asthma severity, Aspirin (HY-14654) sensitivity, and mast cell activation disorders. Leukotriene E4 is a full functional agonist of CysLT1R, which induces sustained intracellular calcium mobilization and Erk phosphorylation. Leukotriene E4 mediates inflammation in a P2Y12 receptor-dependent manner. Leukotriene E4 can be used in the research of asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory diseases. The product specifications provided below refer solely to the active content of Leukotriene E4-d5. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-113465A11-trans Leukotriene E4 -
Similarity Score 0.94
HY-115356Eoxin E4 -
Similarity Score 0.91
HY-18067720-Hydroxyleukotriene E4 -
Similarity Score 0.91
HY-W747567Leukotriene E4 methyl ester -
Similarity Score 0.86
HY-113456SLeukotriene D4-d5 -
Similarity Score 0.85
HY-113456Leukotriene D4 -
Similarity Score 0.85
HY-W74756311-trans Leukotriene D4 -
Similarity Score 0.85
HY-131395N-Acetyl-Leukotriene E4 -
Similarity Score 0.81
HY-13749314,15-Leukotriene D4 -
Explore the MedChemAI to find more analogs
References
- [1]. Foster HR, et al. Leukotriene E4 is a full functional agonist for human cysteinyl leukotriene type 1 receptor-dependent gene expression. Scientific reports. 2016 Feb 02;6:20461.
-
[2]. Paruchuri, S., et al. (2009). Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptor. Journal of Experimental Medicine, 206(11), 2543-2555.
- [3]. Marquette M, et al. Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis. Current allergy and asthma reports. 2022 Dec;22(12):209-229.
